Press release Lund, 18 July 2017
Enzymatica recruits Chief Commercial Officer
Enzymatica has recruited Claus Egstrand as its Chief Commercial Officer. Claus Egstrand's primary responsibility will be to develop Enzymatica's international business, focusing on distributor agreements and also, in the longer term, on the launch of new products. Claus has many years of experience from pharmaceutical and medical technology companies such as Merck & Co, Pfizer, Stryker Corporation, Pharmacia and Johnson&Johnson/Merck Pharmaceuticals.
"There are great growth opportunities for Enzymatica with its patented barrier technology on which the common cold spray ColdZyme® is based. I look forward to being able to contribute with my experience in building successful brands and international pharmaceutical and medical technology companies. My aim is to contribute towards Enzymatica becoming a first-class self-care company in the global market."
"We are delighted to have recruited Claus who, with his experience and contacts in the life science industry, will be key to our international expansion, particularly in contact and negotiations with international partners," says Fredrik Lindberg, CEO of Enzymatica, continuing:
"Claus has an impressive background, having repeatedly demonstrated his ability to lead the build-up of businesses with two-digit growth rates, in terms of both sales and profits."
Claus Egstrand's previous positions have included being Head of Europe for MSD Consumer Care in the pharmaceutical company Merck & Co, Vice President, General Manager Medsurg Europe in the medical device company Stryker Corporation, Senior Vice President Consumer Healthcare for Latin America, Africa, Asia, Japan and Australia in the pharmaceutical company Pfizer, Vice President and head of global marketing for the smoking cessation product Nicorette in the pharmaceutical company Pharmacia and CEO of the Johnson&Johnson/Merck Pharmaceuticals' operation in France. He joins Enzymatica from a position as Group President, International at HOLOGIC CORP.
For more information, contact:
Fredrik Lindberg, CEO of Enzymatica AB Tel: +46 (0)708-86 53 70, e-mail fredrik.lindberg@enzymatica.com
About Enzymatica AB Enzymatica AB is a medical device company that develops and sells medical devices for infection-related diseases. In a short period of time, the company has developed ColdZyme®, a unique mouth spray for the common cold, has launched the product in eight markets and has established it among the top-selling cold products in Swedish kronor terms at Swedish pharmacies. The strategy is to continue to grow by strengthening the company's position in existing markets and expanding into new geographical markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information, visit: www.enzymatica.se Enzymatica's Certified Adviser is Erik Penser Bank.
Attachments:A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/Attachm...ccbd5605e8
